Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma

Inclusion Criteria:

- Confirmed diagnosis of multiple myeloma ISS stage I, II or III, less than 12 months
since initiation of systemic therapy

- ≥8x106 CD34+cells/kg available in cryopreservation in aliquots appropriate for tandem
transplants

- Age: 18-75 years at time of transplantation

- KPS 70-100%

- Recovery from complications of prior therapies

- Gender: There is no gender restriction

Exclusion Criteria:

- Diagnosis other than multiple myeloma

- Chemotherapy or radiotherapy within 21 days of initiating treatment in this study

- Prior autologous or allogeneic transplantation (except as enrolled into this study)

- Uncontrolled bacterial, viral, fungal or parasitic infections

- Uncontrolled CNS metastases

- Known amyloid deposition in heart

- Organ dysfunction

- LVEF <40% or cardiac failure not responsive to therapy

- FVC, FEV1, or DLCO <50% of predicted and/or receiving supplementary continuous oxygen